Israeli Study Links Weight-Loss Drugs to Lower Dementia Risk
תומצת מתוך Arutz Sheva על ידי baba
An Israeli study of nearly 47,000 patients found that GLP-1 medications, used for diabetes and obesity, were associated with a 14% lower risk of dementia. The risk reduction was more pronounced in women (22%) and individuals over 65 (18%). Researchers caution that the study shows a correlation, not causation, and further research is required to confirm a direct link.
הידיעה ב-5 שורות · תקציר של baba
- Israeli study links GLP-1 drugs to 14% lower dementia risk in 47,000 patients.
- Women showed a 22% reduced dementia risk, and those over 65 an 18% reduction.
- Researchers caution the study found a correlation, not definitive causation.
- GLP-1 drugs may protect the brain by reducing inflammation and improving insulin response.
- Further clinical trials are needed to confirm the link and potential preventative benefits.
A large-scale Israeli study involving nearly 47,000 Clalit Health Services patients suggests a potential link between GLP-1 receptor agonist medications, commonly used for diabetes and obesity, and a reduced risk of developing dementia. The research, published in the European Journal of Internal Medicine, found a 14% lower risk of dementia among patients treated with these drugs compared to those on other diabetes medications.
Researchers from institutions including the Hebrew University, Tel Aviv University, Ariel University, and the Technion analyzed over a decade of medical records. While the overall reduction in dementia risk was 14%, the study noted more significant findings in specific demographics. Women taking GLP-1 drugs showed a 22% lower risk, and individuals aged 65 and above had an 18% lower risk.
Professor Dror Dicker, a lead researcher and head of internal medicine at HaSharon Hospital, explained that obesity and diabetes are known to be associated with chronic inflammation, insulin resistance, and vascular damage, all of which can negatively impact brain health and increase dementia risk over time. "The study we conducted shows that GLP-1 family drugs, which have already revolutionized the treatment of obesity and diabetes, may have significant added value in protecting the brain, especially in women and those over 65," Dicker stated.
However, the researchers strongly emphasize that the study identified a correlation, not causation. Dr. Wissam Abu Ahmed, a researcher at Clalit and senior lecturer in biostatistics at the Hebrew University, noted that prior research indicates GLP-1 drugs may also act on brain receptors, potentially reducing neuroinflammation and improving brain cell response to insulin. "Beyond balancing sugar levels and reducing weight, studies indicate that they also act on brain receptors, reduce neuroinflammatory processes, and improve brain cell response to insulin," Abu Ahmed explained.
The study does not prove that medications like Ozempic or Saxenda prevent dementia, nor does it recommend their use for prevention. Further clinical trials are needed to establish a definitive causal relationship, but the findings open possibilities for broader therapeutic approaches in managing diabetes and obesity.
מוזכרים
אותו אירוע, כפי שכל מערכת דיווחה עליו בנפרד. פתחו כמה דיווחים כדי להשוות מה כל מערכת מדגישה, ומה היא משאירה בחוץ.
מרכז 1ימין 2